SCHEMBL4841665

SCHEMBL4841665

O=C1[C@H](N2C(=O)c3ccccc3C2=O)CC=C[C@@H](c2ccc(F)cc2)N1CC1CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE6D O43924 1/20 0.37
KMT2A Q03164 3/20 0.35
TSHR P16473 2/20 0.35
HTR1A P08908 1/20 0.35
HTR2A P28223 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
MEN1 O00255 2/20 0.35
DDB1 Q16531 2/20 0.34
CRBN Q96SW2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
CHRM2 P08172 1/20 0.34
OPRM1 P35372 1/20 0.34
IKZF3 Q9UKT9 1/20 0.34
CYP1A2 P05177 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
MAPT P10636 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
FFAR1 O14842 1/20 0.33
KCNH2 Q12809 1/20 0.33
GRM2 Q14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8312298 1.00 PDE6D (0.37) PDE6DKMT2ATSHRHTR1AHTR2A
SCHEMBL8313412 0.91 ALDH1A1 (0.36) PDE6DKMT2ATSHRMEN1DDB1
SCHEMBL4845001 0.91 ALDH1A1 (0.36) PDE6DKMT2ATSHRMEN1DDB1
SCHEMBL4841426 0.86 ALDH1A1 (0.40) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL8319687 0.86 ALDH1A1 (0.40) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL5791548 0.78 MEN1 (0.36) KMT2AMEN1TDP1MAPTNPSR1
SCHEMBL4833492 0.78 MEN1 (0.36) KMT2AMEN1TDP1MAPTNPSR1
SCHEMBL4841479 0.78 MEN1 (0.36) KMT2AMEN1TDP1MAPTNPSR1
SCHEMBL8313398 0.76 ALDH1A1 (0.42) KMT2AMEN1ALDH1A1TDP1MAPT
SCHEMBL4838497 0.76 ALDH1A1 (0.42) KMT2AMEN1ALDH1A1TDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342007-B2 Lactams and uses thereof ASTRAZENECA AB (SE) 2008-03-11 US disclosed
US-7342007-B2 Lactams and uses thereof ASTRAZENECA AB (SE) 2008-03-11 US disclosed
US-7342007-B2 Lactams and uses thereof ASTRAZENECA AB (SE) 2008-03-11 US disclosed
US-20060183732-A1 Novel lactams and uses thereof ASTRAZENECA AB (SE) 2006-08-17 US disclosed
EP-1636196-A1 NOVEL LACTAMS AND USES THEREOF AstraZeneca AB (SE) 2006-03-22 EP disclosed
WO-2004080983-A1 NOVEL LACTAMS AND USES THEREOF ASTRAZENECA AB (SE) 2004-09-23 WO disclosed
WO-2004080983-A1 NOVEL LACTAMS AND USES THEREOF ASTRAZENECA AB (SE) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183732-A1 Novel lactams and uses thereof BACE1, BACE2, APP PDE6D 2560/4885KMT2A 4366/4885TSHR 4818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.